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Abstract
Background: The safety and tolerability of a new highly purified, urine-derived human menopausal
gonadotropin (hMG) preparation [Menopur(R)] was compared with a currently available hMG
[Repronex (R)] in women undergoing in vitro fertilization (IVF).
Methods: This was a randomized, open-label, parallel-group, multicenter study conducted in
subjects undergoing IVF. Women (N = 125), 18–39 years of age, underwent pituitary down-
regulation with leuprolide acetate beginning 7 days prior to onset of menses and continuing up to
the day before hCG administration. Subjects were randomized to receive subcutaneous (SC)
Menopur (R) (n = 61) or Repronex (R) SC (n = 64) for a maximum of 12 days. All adverse events
(AEs) were recorded and subject self-assessments of injection site reactions were recorded in a
daily diary.
Results: Significantly fewer subjects in the Menopur (R) group reported injection site reactions (P
< 0.001) compared to the Repronex (R) group. Overall, there was no statistically significant
difference in the incidence of AEs between the two treatment groups.
Conclusion:  Menopur (R) SC offers a greater safety and tolerability profile compared to
Repronex (R) SC.
Background
Zondek and colleagues were the first to propose that the
pituitary gland secretes hormones that stimulate the
gonads [1]. This hypothesis was later confirmed with the
identification of two different hormones, follicle-stimu-
lating hormone (FSH) and luteinizing hormone (LH) [2].
These advances in the understanding of the human repro-
ductive process converged in 1958 with the successful
clinical use of pituitary gonadotropins to induce ovula-
tion in anovulatory women [3].
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Development of simple extraction and purification tech-
niques led to the production of human menopausal gona-
dotropins (hMG) in quantities sufficient for clinical use.
In 1962, the first pregnancy resulting from the use of a
urine-derived hMG for follicular stimulation was reported
[4]. Since then, human-derived gonadotropins have
remained a reliable and safe treatment for infertility.
However, the purity of early hMG preparations was low
and the majority of the injectant preparations consisted of
uncharacterized urinary proteins [5]. The uncharacterized
proteins produced adverse injection site reactions when
administered intramuscularly (IM) and the product could
not be administered subcutaneously (SC). Newer purifi-
cation techniques applied to the manufacturing of hMG
resulted in enhanced purity and enabled SC administra-
tion. However, mild to moderate injection site reactions
were still common. Most recently, modern day purifica-
tion techniques have resulted in the availability of a new,
high purity hMG preparation that has nearly eliminated
injection site reactions.
The purification process for Repronex® included at least 24
steps involving adsorptions, dialysis and precipitations, as
well as ionic, cationic, and hydrophobic exchange chro-
matography [6]. Advances in these manufacturing tech-
niques and the inclusion of additional purification steps
have now produced a new highly purified hMG
(Menopur® , 75 IU LH:75 IU FSH; Ferring Pharmaceuticals
Inc., Suffern, New York) that is nearly devoid of uncharac-
terized proteins. This high purity hMG was developed to
reduce the frequency of injection site reactions. Therefore,
we conducted a clinical trial to compare the safety and tol-
erability of Menopur® with the currently available hMG
preparation, Repronex® (75 IU LH:75 IU FSH; Ferring
Pharmaceuticals Inc.) in women undergoing controlled
ovarian hyperstimulation (COH) for in vitro fertilization
(IVF).
Methods
This was a randomized, open-label, parallel-group, multi-
center study comparing one cycle of treatment with
Menopur® SC or Repronex® SC at a dose of 75 to 450 IU/
day administered as a single, daily injection for up to 12
days in infertile women undergoing COH for IVF. Each
subject participated in only one cycle of IVF. Fifteen cent-
ers participated in the study, each of which obtained insti-
tutional review board approval. Written informed consent
was obtained from all participants prior to screening and
study enrollment.
Subjects
Subjects had to meet the following eligibility criteria to
participate in the study: nonsmoking, 18 to 39 years of age
with regular ovulatory cycles (24 to 35 days); have a diag-
nosis of unexplained infertility or infertility due to tubal
factor; stage I or II endometriosis; normal ovaries and
uterus on transvaginal ultrasonography; normal serum
levels of estradiol (E2), prolactin, LH, FSH, testosterone,
dehydroepiandrosterone sulfate, and thyroid-stimulating
hormone; and have a body mass index of ≤ 34. In addi-
tion, all subjects were seronegative for hepatitis B and C
and HIV and had a negative pregnancy test prior to initi-
ating treatment. A semen analysis performed on a sample
from either the subject's partner or the designated donor
had to be normal according to the criteria established by
the World Health Organization. A minimum of one men-
strual cycle without IVF/assisted reproductive therapy
(ART) treatment was required prior to screening. Subjects
were excluded from participation if there was evidence of
any clinically relevant systemic disease or any surgical or
medical condition that could interfere with the absorp-
tion, metabolism, or excretion of gonadotropins. Subjects
were not to have had a positive pregnancy test within
three months of baseline screening and were also
excluded from the study if they had undergone three or
more prior ART cycles, had abnormal uterine bleeding, a
history of substance abuse, a history of chemotherapy,
were breast feeding, or if they had participated in any
experimental drug study within 60 days of screening for
this study.
Protocol
Each eligible subject received daily injections of leupro-
lide acetate (LA; TAP Pharmaceuticals, Deerfield, IL; 0.5
mg/d SC) beginning 7 days prior to the anticipated onset
of menses until the day before administration of human
chorionic gonadotropin (hCG)(Novarel™, Ferring Phar-
maceuticals Inc., Suffern, NY). LA was continued until
there was evidence of down-regulation as indicated by a
serum E2 concentration of ≤ 45 pg/mL and an endometrial
lining ≤ 7 mm on transvaginal ultrasound. If the E2 level
was ≥ 45 pg/ml, the endometrial lining was > 7 mm, or
menses did not occur within 20 days after beginning LA,
the subject was withdrawn from the study.
Subjects who met the down-regulation criteria listed
above were randomized to receive single, daily doses of
Menopur® SC or Repronex® SC. They were instructed to
self-administer hMG SC, alternating their injections
between the right and left lower abdomen at approxi-
mately the same time every afternoon. Subjects were also
instructed to record injection site pain each day using a 0-
to 10-point scale, with 0 representing no pain and 10 rep-
resenting extreme pain. In addition, subjects recorded all
adverse events (AEs) experienced during the study, includ-
ing those associated with injection site reactions. Subjects
received 225 IU for 4 days and on day 5, subjects returned
to the study centers for transvaginal ultrasound and deter-
mination of E2 levels. Based on these findings, the investi-
gators adjusted the daily dose of hMG by 75 to 150 IU upReproductive Biology and Endocrinology 2005, 3:62 http://www.rbej.com/content/3/1/62
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to a maximum of 450 IU per day. Serum E2 levels and
ultrasound measurements were taken prior to each dose
escalation and a maximum of 12 days total hMG treat-
ment was allowed. Investigators were permitted to
decrease the hMG dose at any time based on clinical judg-
ment and safety concerns, and could discontinue hMG
and/or withhold hCG administration if they believed the
subject was at risk for development of ovarian hyperstim-
ulation syndrome (OHSS). When at least 3 follicles
reached a diameter of ≥ 16 mm as measured by transvagi-
nal ultrasound and E2 levels were appropriate for the
number of follicles observed based on the investigator's
clinical judgment, hMG was discontinued and hCG
(Novarel™, Ferring Pharmaceuticals, Inc.) was adminis-
tered IM at a dose of 10,000 USP units. Oocytes were
retrieved 34 to 36 hours later. Standard center-specific IVF
culture conditions were allowed, however intracytoplas-
mic sperm injection (ICSI) and assisted hatching were
not. Study centers were permitted to use coculture with
homologous cells if it was standard practice and routinely
used in all subjects undergoing IVF at that center. A maxi-
mum of four embryos could be transferred. Progesterone
(Crinone™ 8% gel, 90 mg qd, Serono Laboratories, Inc.,
Randolph, MA) was self-administered beginning on day 2
or day 3 after oocyte retrieval for luteal phase support, and
continued until there was fetal heart motion in an intrau-
terine pregnancy or there was a negative serum pregnancy
test (β-hCG).
Throughout the study, investigators recorded the presence
and nature of any AEs. Within 3 weeks of the initial β-hCG
quantitative serum pregnancy test or discontinuation
from study, subjects returned to the study center for an
exit physical examination. Subject reports of AEs were
recorded on the case report form and tabulated using
Coding Symbols for Thesaurus of Adverse Reaction Terms
(COSTART) terminology. Subjects' daily diary evaluations
of injection site pain were tabulated on a 0- to 10-point
scale.
Statistical evaluation
The primary efficacy of this study was oocytes retrieved
and therefore power calculations were done with 80%
power to detect an among group difference of 30% in the
number of oocytes retrieved. This required 59 patients per
group.
A chi-square test was used to make between group com-
parisons on the percentage of subjects with at least one AE
and at least one mild to moderate AE while a Fisher exact
test was used to make comparisons on the percentage of
subjects with at least one severe AE and at least one serious
AE. A chi-square test was used to test for differences in the
percentage of subjects with abnormal findings recorded at
the study exit physical examination, while the Fisher exact
test was used to test for differences in the percentage of
subjects with clinically significant abnormal findings. The
initial analysis of injection site pain on each treatment day
compared the two treatment groups using a one-way
ANOVA. A linear mixed model was then used to make
treatment comparisons of injection site pain throughout
the study. This model allowed the analysis of continuous
correlated data to account for within subject variation.
Results
A total of 190 subjects were randomized and included in
the analysis of safety. The initial study contained a third
arm consisting of 65 subjects who received Menopur® IM,
however these data were not included in this analysis, as
the focus of this report is to compare the safety and toler-
ability of Repronex® SC and Menopur® SC. The remaining
125 subjects were randomized to receive Menopur® SC (n
Subjects with hMG-Associated Injection Site Reactions Figure 1
Subjects with hMG-Associated Injection Site Reac-
tions. This figure shows the percentage of subjects with any 
hMG associated injection site reaction as well as those with 
reactions that included welts or inflammation and those 
whose reactions involved swelling.
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Table 1: Demographic Characteristics of Subjects*
Characteristic Menopur® (n = 61) Repronex® (n = 64)
Age (yrs) 32.3 (3.7) 32.5 (4.1)
Weight (kg) 63.5 (11.0) 63.5 (10.0)
Height (cm) 161.5 (7.4) 163.3 (6.4)
Body mass index 
(kg/m2 )
24.4 (3.6) 24.0 (3.4)
Race, no. (%)
Caucasian 47 (77.0) 54 (84.4)
African-American 7 (11.5) 1 (1.6)
Asian 0 (0) 2 (3.1)
Hispanic 5 (8.2) 5 (7.8)
Native American 0 (0) 0 (0)
Other 2 (3.3) 2 (3.1)
*Values are mean (SD).Reproductive Biology and Endocrinology 2005, 3:62 http://www.rbej.com/content/3/1/62
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= 61) or Repronex® SC (n = 64). Due to subject noncom-
pliance or loss at follow-up, certain safety outcomes such
as exit physical examination variables and injection site
pain are missing a few data points.
Subject demographic characteristics are summarized in
Table 1. Overall, subjects in the two treatment groups
were comparable both demographically and medically.
The only statistically significant difference between the
groups was race, with African-Americans comprising
11.5% of the Menopur® group compared with 1.6% of the
Repronex® group (P = 0.039). The impact of this difference
is unknown.
There were no statistically significant differences between
the treatment groups in the number of subjects with any
AEs, severe AEs, or serious AEs, as shown in Table 2. There
were five serious AEs during the study (1 subject in the
Menopur®  group had OHSS and four subjects in the
Repronex® group had one of the following serious AEs:
dehydration, an ectopic pregnancy, a right ruptured ovary
with secondary hemothorax, and a pelvic abscess). A total
of three cases of OHSS were reported (1 subject in the
Menopur® group, which was severe and 2 subjects in the
Repronex® group, which were mild or moderate).
Table 3 lists the AEs with an incidence of ≥ 5% (2 or more
subjects). Among these AEs, there were no significant dif-
ferences between the two groups in the percentage of sub-
jects with any AE and no difference in the intensity of
injection site pain. However, there were numerically fewer
total AEs in the Menopur® group (n = 131) compared to
the Repronex® group (n = 198). As shown in Figure 1, this
difference was largely attributed to the number of injec-
tion site reactions, the single most common AE. When
only hMG injections were considered, there were only
three (4.9%) subjects in the Menopur® group that reported
injection site reactions, whereas 22 (34.4%) subjects in
the Repronex® group reported injection site reactions (P <
0.001). Among the three Menopur® subjects with local
injection site reactions, all were transient and mild to
moderate in intensity, none developed welts/inflamma-
tion, and only one subject had localized swelling. These
findings contrasted with the 22 subjects in the Repronex®
group with injection site reactions, among whom eight
developed welts/inflammation (P < 0.001) and four
developed swelling (P = 0.328). Conversely, there was no
difference in mean scores for injection site pain between
the two groups, 2.6 for Menopur® and 2.3 for Repronex® (P
= 0.615).
Discussion
Overall, the safety profile of Menopur® in this study was
similar to that of Repronex® . Human-derived gonadotro-
pins have been used safely and effectively in ART proto-
cols for over forty years. However, the injection of
partially purified hMG is associated with more injection
site reactions than highly purified gonadotropins.
Removal of nearly all uncharacterized proteins from hMG
in the manufacturing process for Menopur® has resulted in
significantly fewer reported injection site reactions in IVF
subjects. There was a seven-fold difference in the percent-
age of subjects with injection site reactions, 4.9% and
34.4% of subjects in the Menopur® and Repronex® groups,
respectively. When the incidence of reactions that
involved swelling, inflammation, or welts was examined,
98% of subjects receiving Menopur® completed their cycle
without such reactions while only 81% of subjects receiv-
ing Repronex® did not experience such events (P = 0.001).
An analysis of Menopur® has shown that its purity and
quality is comparable to recombinant gonadotropin prep-
arations [7]. In addition, Menopur® has been shown to
have a similar safety and tolerability profile as recom-
binant FSH in women undergoing IVF/ICSI treatment
cycles [8]. Collectively, these observations and studies,
combined with the data from this study demonstrate that
Table 3: Subjects with Adverse Events: Incidence Rate ≥ 5%* 
(two or more subjects)
Adverse Event Menopur® n = 61 Repronex® n = 64
Abdominal cramps 13 (21.3) 14 (21.9)
Headache 13 (21.3) 13 (20.3)
Post retrieval pain 7 (11.5) 9 (14.1)
Nausea 6 (9.8) 10 (15.6)
Vaginal spotting 6 (9.8) 5 (7.8)
Abdominal fullness 5 (8.2) 7 (10.9)
Abdominal pain 5 (8.2) 4 (6.3)
Constipation 5 (8.2) 1 (1.6)
Respiratory disorder 4 (6.6) 4 (6.3)
Vaginal hemorrhage 2 (3.3) 4 (6.3)
Breast tenderness/pain 2 (3.3) 5 (7.8)
Malaise 2 (3.3) 4 (6.3)
Sinusitis 2 (3.3) 4 (6.3)
*Values represent numbers (percentage) of subjects with adverse 
event.
Table 2: Subjects with Adverse Events*
Adverse 
Event
Menopur® (n = 61) Repronex® (n = 64) P Value
Any 41 (67.2) 48 (75.0) 0.620
Severe 5 (8.2) 5 (7.8) 0.402
Serious 1 (1.6) 4 (6.3) 0.456
*Values represent numbers (percentage) of subjects with one or more 
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Menopur® is at least as efficacious and safe as any existing
gonadotropin.
The results from this study demonstrate that Menopur® , a
new highly purified hMG, can be administered SC with
significantly fewer injection site reactions than Repronex®
, a partially purified hMG. Thus, advanced manufacturing
techniques have produced the first ever highly purified
form of hMG resulting in a markedly improved safety and
tolerability profile compared with previously available
hMG products.
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